

**Table S16**

*Progressive Supranuclear Palsy: Study Design Details and Participant Characteristics for Singing as a Treatment Modality*

Source	N	Study design	Sex (% female)	Age range (years)	Dysarthria type	Inclusion/exclusion criteria	Inferential statistics	Power analysis	Control group	Baseline data collected	Control intervention	Number of treatment sessions	Mode of treatment delivery	Home exercise plan	Patient-reported outcomes	Treatment effect size
Tamplin et al. (2019)	75 *	Prospective, quasi-experimental	39.00%	51-93	NR	Inclusion 1: <ul style="list-style-type: none"> <li>(atypical PD not excluded)</li> <li>English speakers</li> <li>Normal cognition (MMSE &gt;24) or mild cognitive impairment (MMSE 18-23) with mandatory caregiver support</li> </ul> Exclusion: 2, 3	Yes	No	Yes	Yes – single baseline	Yes	Weekly group: 12 sessions; Monthly group: unspecified number of sessions for 3 months	In person, group	No	Yes	No
Tamplin et al. (2020)	75 **	Prospective, quasi-experimental	39.00%	51-93	NR	Inclusion 1: <ul style="list-style-type: none"> <li>PD or a caregiver to a person with PD</li> <li>Communication change in person with PD (per self-report, caregiver or health professional)</li> </ul> Exclusion: 2, 3	Yes	No	Yes	Yes – single baseline	Yes	2 hours of weekly or monthly treatment for 12 months	In person, group	No	Yes	No

*Note.* NR, Not Reported. PD, Parkinson's disease. MMSE, Mini-Mental State Examination. Inclusion criteria: <sup>1</sup>Parkinson's disease. Exclusion criteria: <sup>2</sup>Moderate to severe cognitive impairment/MMSE <18 or memory problems; <sup>3</sup>Severe language problems or hearing impairment. \**n* = 67 with Parkinson's disease, *n* = 5 with Lewy body dementia, *n* = 2 with progressive supranuclear palsy, *n* = 1 with multiple system atrophy. \*\* *n* = 71 with Parkinson's disease, *n* = 2 with progressive supranuclear palsy, *n* = 2 with multiple system atrophy.